What is driving PRFN.SW stock’s intraday move today?

The intraday move is driven by heavy volume and speculative trading around Kinarus Therapeutics' clinical-stage news flow. No scheduled earnings were listed and liquidity on the SIX exchange amplified the price swing.

How risky is PRFN.SW stock for investors?

PRFN.SW stock is high risk. Metrics show negative EPS, thin cash per share and low market depth. Elevated volume can produce sharp moves and potential dilution risk from future financings.

What price does Meyka AI model forecast for PRFN.SW stock?

Meyka AI's forecast model projects a base price target of CHF0.0500 versus the current CHF0.0362, implying upside of about 38.12%. Forecasts are model projections and not guarantees.

Where can I find official information on Kinarus Therapeutics?

Official company information and investor resources are on the Kinarus Therapeutics website at [Kinarus Therapeutics](https://www.kinarus.com). Market quote and financial data are on public data services such as FinancialModelingPrep.

CH Stocks

CHF0.0362 intraday dip: PRFN.SW Kinarus (SIX) most-active 26 Feb 2026

ByDanny Kontos February 26, 2026February 26, 2026

PRFN.SW stock opened the intraday session at CHF0.0400 and traded down to CHF0.0362 by mid-session on 26 Feb 2026. Volume is elevated at 2,937,350 shares versus an average of 859,130, marking it among the SIX most-active names. The move follows thin market depth and ongoing clinical-stage updates from Kinarus Therapeutics Holding AG. We track price action, liquidity and short-term catalysts that could extend the slide or trigger a rebound in this small-cap Swiss biotech.